HK Stock Market Move | HUTCHMED (00013) rose over 3% in late trading; ATTC licensed to GSK; institutions say the company's overseas expansion path is clear.

HUTCHMED (00013) rose over 3% in late trading. As of press time, it was up 2.72% at HK$21.9, with a turnover of HK$90.5696 million. On the news front, on September 3, the company announced an exclusive licensing agreement with GSK for HMPL-A830 (KRAS-EGFR ATTC), under which GSK obtained overseas rights for an upfront payment/milestones of US$110 million/US$1.185 billion. Huafu Securities said it is bullish on HMPL-A830's potential to enter the unmet KRAS-mutant CRC market with a differentiated mechanism, and recommended closely tracking the Phase I data readout. Huatai said that A830 secured a major BD deal, validating the global value of the ATTC platform. The company is expected to initiate a global Phase I trial in 2H26, while global Phase I trials for A251 and A580 are progressing smoothly, with multiple molecules expected to enter clinical development successively. It is bullish on the company's continued overseas expansion. Previously, the company reached multiple overseas BD deals with MNCs such as AstraZeneca and Takeda, and the overseas commercialization of the relevant molecules is gradually being realized. Among them, overseas sales of fruquintinib continued to grow steadily, and in 8M26, savolitinib achieved positive PFS/OS in the global Phase III trial for 2L NSCLC, with FDA submission expected soon.